A Wake Forest study will publish the results shorty.  Rosiglitazone and pioglitazone, both with scarlet letters of their own (increases in cardiovascular risk) will also have to carry the burden of increasing fracture risk in women (but not men) over 55.  Sure, the fine print will have to be fleshed out, but the news places the burden on the prescriber to, once again, refer back to the ever-so-important ratio of risk versus benefit. | LINK

Related Posts Within Doctor Pundit:

1. UK Study: Drugs Used in Alzheimer Patients Double Risk of Mortality What should I do as a physician rounding on one...
2. Is There a Link Between Coffee Consumption in Women and Possible Lower Stroke Risk? The news out of Javaland continues to extol the benefits...
3. NEJM Study: Two Popular Blood Thinners Effective for Stroke Risk Reduction in Appropriate Candidates No April Fool’s Joke here. A new study shows combining...
4. FDA Stalls on Approval of New Anti-Diabetic Agent At the dusk of the first decade of the 21st...
5. Popular Smoking Cessation Drug Increases Adverse Cardiac Risk First, and almost immediately out of the box, it was...